Effect of statins on breast cancer recurrence and mortality: a review

Renae D Van Wyhe,1,2 Omar M Rahal,1 Wendy A Woodward1 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2Baylor College of Medicine, Houston, TX, USA Abstract: Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are medications that have been u...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Van Wyhe RD, Rahal OM, Woodward WA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	statins HMG-CoA reductase inhibitors breast cancer inflammatory breast cancer triple-negative breast cancer locoregional recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f86c35c0ce7e4f029e274d73511b9296
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f86c35c0ce7e4f029e274d73511b9296
record_format	dspace
spelling	oai:doaj.org-article:f86c35c0ce7e4f029e274d73511b92962021-12-02T02:16:13ZEffect of statins on breast cancer recurrence and mortality: a review1179-1314https://doaj.org/article/f86c35c0ce7e4f029e274d73511b92962017-12-01T00:00:00Zhttps://www.dovepress.com/effect-of-statins-on-breast-cancer-recurrence-and-mortality-a-review-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Renae D Van Wyhe,1,2 Omar M Rahal,1 Wendy A Woodward1 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2Baylor College of Medicine, Houston, TX, USA Abstract: Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are medications that have been used for decades to lower cholesterol and to prevent or treat cardiovascular diseases. Since their approval by the US Food and Drug Administration in the 1980s, other potential uses for statins have been speculated on and explored. Basic science and clinical research suggest that statins are also effective in the management of breast cancer. Specifically, in various breast cancer cell lines, statins increase apoptosis and radiosensitivity, inhibit proliferation and invasion, and decrease the metastatic dissemination of tumors. Clinical trials in breast cancer patients support these laboratory findings by demonstrating improved local control and a mortality benefit for statin users. A role for statins in the management of aggressive breast cancers with poor outcomes – namely, inflammatory breast cancer and triple-negative breast cancer – is particularly implicated. However, data exist showing that statins may actually promote invasive breast disease after long-term use and thus should be prescribed cautiously. Furthermore, a general consensus on the type of statin that should be administered, for how long, and when in relation to time of diagnosis is lacking. Given their low toxicity profile, affordability, and ease of use, consideration of statins as a therapy for breast cancer patients is imminent. In this review, we summarize current evidence regarding statins and clinical breast cancer outcomes, as well as discuss potential future studies that could shed light on this increasingly relevant topic. Keywords: statins, HMG-CoA reductase inhibitors, breast cancer, inflammatory breast cancer, triple-negative breast cancer, locoregional recurrenceVan Wyhe RDRahal OMWoodward WADove Medical PressarticlestatinsHMG-CoA reductase inhibitorsbreast cancerinflammatory breast cancertriple-negative breast cancerlocoregional recurrenceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 9, Pp 559-565 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	statins HMG-CoA reductase inhibitors breast cancer inflammatory breast cancer triple-negative breast cancer locoregional recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	statins HMG-CoA reductase inhibitors breast cancer inflammatory breast cancer triple-negative breast cancer locoregional recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Van Wyhe RD Rahal OM Woodward WA Effect of statins on breast cancer recurrence and mortality: a review
description	Renae D Van Wyhe,1,2 Omar M Rahal,1 Wendy A Woodward1 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2Baylor College of Medicine, Houston, TX, USA Abstract: Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are medications that have been used for decades to lower cholesterol and to prevent or treat cardiovascular diseases. Since their approval by the US Food and Drug Administration in the 1980s, other potential uses for statins have been speculated on and explored. Basic science and clinical research suggest that statins are also effective in the management of breast cancer. Specifically, in various breast cancer cell lines, statins increase apoptosis and radiosensitivity, inhibit proliferation and invasion, and decrease the metastatic dissemination of tumors. Clinical trials in breast cancer patients support these laboratory findings by demonstrating improved local control and a mortality benefit for statin users. A role for statins in the management of aggressive breast cancers with poor outcomes – namely, inflammatory breast cancer and triple-negative breast cancer – is particularly implicated. However, data exist showing that statins may actually promote invasive breast disease after long-term use and thus should be prescribed cautiously. Furthermore, a general consensus on the type of statin that should be administered, for how long, and when in relation to time of diagnosis is lacking. Given their low toxicity profile, affordability, and ease of use, consideration of statins as a therapy for breast cancer patients is imminent. In this review, we summarize current evidence regarding statins and clinical breast cancer outcomes, as well as discuss potential future studies that could shed light on this increasingly relevant topic. Keywords: statins, HMG-CoA reductase inhibitors, breast cancer, inflammatory breast cancer, triple-negative breast cancer, locoregional recurrence
format	article
author	Van Wyhe RD Rahal OM Woodward WA
author_facet	Van Wyhe RD Rahal OM Woodward WA
author_sort	Van Wyhe RD
title	Effect of statins on breast cancer recurrence and mortality: a review
title_short	Effect of statins on breast cancer recurrence and mortality: a review
title_full	Effect of statins on breast cancer recurrence and mortality: a review
title_fullStr	Effect of statins on breast cancer recurrence and mortality: a review
title_full_unstemmed	Effect of statins on breast cancer recurrence and mortality: a review
title_sort	effect of statins on breast cancer recurrence and mortality: a review
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/f86c35c0ce7e4f029e274d73511b9296
work_keys_str_mv	AT vanwyherd effectofstatinsonbreastcancerrecurrenceandmortalityareview AT rahalom effectofstatinsonbreastcancerrecurrenceandmortalityareview AT woodwardwa effectofstatinsonbreastcancerrecurrenceandmortalityareview
_version_	1718402630747684864

Effect of statins on breast cancer recurrence and mortality: a review

Ejemplares similares